SCHEMBL1641018

SCHEMBL1641018

O=C(NCc1ccc(Cl)c(Cl)c1)c1cn(Cc2ccc(Br)cc2F)c(=O)cc1O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.49
CNR2 P34972 2/20 0.49
MEN1 O00255 2/20 0.42
HPGD P15428 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
AKR1B1 P15121 2/20 0.42
BRD4 O60885 1/20 0.41
BRD2 P25440 1/20 0.41
BRD3 Q15059 1/20 0.41
BRDT Q58F21 1/20 0.41
WDR5 P61964 1/20 0.39
APEX1 P27695 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RORC P51449 1/20 0.37
TAOK1 Q7L7X3 1/20 0.37
TAOK3 Q9H2K8 1/20 0.37
TSHR P16473 1/20 0.37
KLKB1 P03952 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641394 0.88 CNR1 (0.53) CNR1CNR2MEN1HPGDKMT2A
SCHEMBL1642162 0.87 LMNA (0.43) CNR1CNR2HPGDWDR5KLKB1
SCHEMBL1641080 0.82 LMNA (0.47) CNR1CNR2MEN1KMT2ASMN1; SMN2
SCHEMBL1641104 0.81 EGLN3 (0.58) CNR1CNR2MEN1HPGDKMT2A
SCHEMBL1641375 0.81 HSP90AA1 (0.53) CNR1CNR2MEN1HPGDKMT2A
SCHEMBL1642234 0.80 WDR5 (0.46) CNR1CNR2MEN1HPGDKMT2A
SCHEMBL1642299 0.76 MAPT (0.47) MEN1HPGDKMT2AAKR1B1BRD4
SCHEMBL1640586 0.75 TSHR (0.50) CNR1CNR2MEN1HPGDKMT2A
SCHEMBL1642131 0.74 CNR1 (0.51) CNR1CNR2BRD4BRD2BRD3
SCHEMBL5464898 0.71 AKR1B1 (0.67) CNR1KMT2ASMN1; SMN2AKR1B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2306828-A1 PROLYL HYDROXYLASE INHIBITORS Glaxosmithkline LLC (US) 2011-04-13 EP disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 CNR1 2636/4885CNR2 2738/4885MEN1 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.